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Abstract Background
 
Leptin is a secreted adipocyte hormone that plays a key role in the regulation
of body weight homeostasis. The leptin effect on human white adipose tissue (WAT) is still
debated.
 
Objective
 
The aim of this study was to assess whether the administration of polyethylene
glycol-leptin (PEG-OB) in a single supraphysiological dose has transcriptional effects on
genes of WAT and to identify its target genes and functional pathways in WAT.
 
Materials and methods
 
Blood samples and WAT biopsies were obtained from 10 healthy
nonobese men before treatment and 72 h after the PEG-OB injection, leading to an
approximate 809-fold increase in circulating leptin. The WAT gene expression profile before
and after the PEG-OB injection was compared using pangenomic microarrays. Functional
gene annotations based on the gene ontology of the PEG-OB regulated genes were performed
using both an ‘in house’ automated procedure and GenMAPP (Gene Microarray Pathway
Profiler), designed for viewing and analyzing gene expression data in the context of biological
pathways.
 
Results
 
Statistical analysis of microarray data revealed that PEG-OB had a major down-
regulated effect on WAT gene expression, as we obtained 1822 and 100 down- and up-
regulated genes, respectively. Microarray data were validated using reverse transcription
quantitative PCR. Functional gene annotations of PEG-OB regulated genes revealed that
the functional class related to immunity and inflammation was among the most mobilized
PEG-OB pathway in WAT. These genes are mainly expressed in the cell of the stroma vascular
fraction in comparison with adipocytes.
 
Conclusion
 
Our observations support the hypothesis that leptin could act on WAT,
particularly on genes related to inflammation and immunity, which may suggest a novel leptin
target pathway in human WAT.
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Introduction
 
The leptin hormone is mainly produced by the white adi-
pose tissue (WAT) and plays a key role in body weight
homeostasis [1]. The changes in circulating leptin levels
reflect the nutritional status and provides a feedback signal
from the periphery to the central nervous system [1,2].
Thus, leptin satisfies the criteria for the long-sought ‘Lipo-
stat’ molecule of the adipostatic model, which was postu-
lated to explain the relative stability of weight over time. In
healthy animals [3], as in humans [4], circulating concen-
trations of leptin are highly correlated with body fat mass;
it crosses the blood–brain barrier and interacts with neu-
rones known to decrease food intake and stimulate thermo-
genesis [5]. In addition to its central action on food intake
and energy expenditure, leptin may also be endowed with
direct peripheral effects on nonadipose tissue (i.e. muscle,
liver, haematopoetic cells) to exert a role on different func-
tional pathways such as angiogenesis, inflammation and
immunity as well as fat oxidation [6–9]. However, the
peripheral effect of leptin on adipose tissue physiology is still
debated [10,11].
Leptin appears as a survival hormone aimed at maintain-
ing the energy balance, representing the first strategy for
obesity treatment. Unfortunately, except for the rare forms
of monogenic obesity with leptin deficiency [12], the major-
ity of obesity cases are associated with high levels of circu-
lating leptin, and the emerged idea was that obese patients
are resistant to the action of leptin [13]. Human trials per-
formed with leptin treatment have shown that most subjects
are unlikely to respond to pharmacological treatment with
this hormone [14–16]. The widespread occurrence of leptin
resistance might reflect the fact that the inability to store
energy efficiently at times of abundance is evolutionarily dis-
advantageous. According to this alternative view, leptin has
a broader physiological role and evolved as a signal whose
reduction indicates starvation [17]. In some cases, leptin
induces moderate fat loss especially under conditions of
energy restriction indicating some action of leptin on WAT
[14,18]. The physiological functions related to this feedback
signal, which can eventually be modulated in adipose tissue
by leptin treatment, are mostly unknown.
In this study, we hypothesized that even if leptin admin-
istration had a limited effect on body fat loss, it could act
on gene expression of known or unknown targets in WAT.
Our purpose was to identify gene targets and functional
pathways of leptin in human adipose tissue. To this end, we
compared gene expression profiles in WAT of seven lean
male subjects before and after 72 h of administration lead-
ing to a high peak of leptin in the circulation. In order to
capture functions that might be significantly affected by
PEG-OB treatment, different methods of gene annotation
were used. Our results showed that functional processes
related to immunity and inflammation were among the most
affected functions after PEG-OB treatment in WAT of
healthy nonobese subjects.
 
Materials and methods
 
PEG-OB
 
Modification of proteins through covalent linkage of poly-
ethylene glycol polymers to the proteins results in reduced
immunogenicity and increased serum half-life for many pro-
teins. Recombinant native human PEG-OB, expressed and
purified from 
 
Escherichia coli
 
, was chemically conjugated to
a species of branched PEGs with an average molecular mass
of 42 kDa in a 1 : 1 ratio. PEG is not metabolized and
excreted completely. The result was a globular PEG–native
human PEG-OB polymer with increased molecular size. A
volume of 1·3 mL PEG-OB at a concentration of 10 mg mL
 
−
 
1
 
was placed in sterile glass vials (Hoffmann-La Roche Inc.,
Nutley, NJ). Preclinical studies with PEG-OB indicate an
extended half-life (> 48 h) and efficacy for reduction of food
intake and body weight in animals [19]. Our previous study
in obese male subjects clearly showed sustained elevated blood
concentrations after weekly subcutaneous dosing of PEG-
OB in humans. Mean peak serum PEG-OB concentrations
were achieved 72 h after dosing, followed by a return to the
elevated predose concentrations after 1 week [15].
Table 1 Clinical and biochemical characteristics of nonobese men treated with a single supraphysiological dose of polyethylene glycol-
OB protein
 
 
Before PEG-OB injection (day 0) After PEG-OB injection (day 3)
Number 10 10
Age (y) 25·9 ± 4·1 –
Weight (kg) 77·65 ± 3·07 77·5 ± 3·1
BMI (kg m−2) 23·1 ± 0·65 23·1 ± 0·62
Leptin (µmol L−1) 2·61 ± 0·75 2111·4 ± 175·53*
Insulin (U mL−1) 5·82 ± 1·08 6·09 ± 1·36
Adiponectin (µg mL−1) 7·61 ± 0·93 7·19 ± 0·91
HsCRP (mg dL−1) 0·134 ± 0·053 0·293 ± 0·13
SAA (µg mL−1) 5·31 ± 1·58 17·82 ± 7·06
Data are expressed as mean ± SEM.
PEG-OB, polyethylene glycol-OB protein.
*Mean fold increase of circulating leptin is approximately 809-fold.
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Subjects and study design
 
Ten nonobese caucasian men (age 21–27 years, body mass
index 20–26 kg m
 
−
 
2
 
) were recruited through a local advert-
isement. All subjects had a stable weight and were healthy
according to their medical history, clinical examination and
routine laboratory findings. The study was approved by the
medical Ethics Committee of the University of Maastricht,
and all participants gave written informed consent. The
leptin treatment consisted of an 80-mg PEG-OB injection
in the para-umbilical region. Blood and WAT biopsies were
obtained from fasted subjects on day 0 (before the PEG-
OB treatment) and 72 h after the injection. At this time,
PEG-OB concentration was approximately 809-fold higher
compared with basal levels (Table 1).
 
Biochemical measures
 
Plasma leptin levels were measured by a double-antibody
sandwich ELISA using a monoclonal antibody specific for
human leptin. This assay measures total leptin [15]. Serum
insulin (mU L
 
−
 
1
 
) was measured with immunoradiometric
assay (IRMA) (Bi-INSULINE IRMA CisBio International,
Gif-sur-Yvette, France). Serum adiponectin concentrations
were determined using standard kits (Linco Research, Saint
Louis, MI). High sensitive C reactive protein circulating levels
were measured using an IMMAGE automatic immuno-
assay system (Beckmann-Coulter, Fullerton, CA).
 
Total RNA preparation
 
Human white subcutaneous adipose tissues were homo-
genized in lysis buffer (RLT buffer, Qiagen, Cour taboeuf,
France) using a rotator-stator, followed by a chloroform
delipidation step. The upper aqueous phase was processed
for total RNA extraction using silica-based spin columns
(RNeasy Mini Kit, Qiagen Protocol). The yield of WAT total
RNA was 3–7 
 
µ
 
g g
 
−
 
1
 
 WAT. The RNA concentration was
determined by measuring absorbance at 260 nm and the
purity was estimated by 260/280 nm absorbance ratio. Total
RNA integrity was verified by agarose gel electrophoresis
or using an Agilent 2100 Bioanalyser (Agilent, Paris, France).
We obtained high-quality RNA, mandatory for microarray
in seven subjects.
A reference pool containing adipose tissue RNAs from
14 healthy subjects was used to compare data from different
experiments. Equivalents of 15 
 
µ
 
g of total RNA from each
of the 14 healthy subjects were mixed together in order to
constitute a pool of total RNA [20].
 
RNA amplification and microarray experiments
 
RNA preparations from the seven subjects were amplified
using MessageAmp aRNA protocol (Ambion, Cambridge-
shire, UK) in order to generate a sufficient amount of
labelled hybridization samples to cDNA microarrays [20].
Briefly, the procedure consists of reverse transcription of
5 
 
µ
 
g total RNA using Primer Oligo dT bearing a T7 pro-
moter sequence, followed by 
 
in vitro
 
 T7 RNA polymerase
transcription of cDNA to generate RNA antisense copies
of each messenger RNA. This amplification procedure is
now generally accepted and it has been demonstrated that
it does not distort the relative abundance of a single mRNA
within a RNA population [21]. Briefly, 3 
 
µ
 
g antisense RNA
was labelled by incorporating Cyanine dyes (Amersham
Pharmacia Biotech, Orsay, France) during random
reverse transcription with Cyscript (Cyscribe first-strand
cDNA labelling kit, Amersham Pharmacia Biotech). Ampli-
fied RNA from the seven healthy men before and after PEG-
OB treatment was labelled with Cy5, whereas amplified
RNA from the reference pool was labelled with Cy3. The
labelled mixture (Cy5 and Cy3) was purified and concen-
trated using Microcon YM 30 column (Millipore, Bedford,
MA) after the addition of human cot-1, yeast tRNA and
poly A. After denaturation of probes, the mixture was
hybridized overnight on 14 slides (seven slides both before
and after treatment) at 65 
 
°
 
C in a sealed humidified hybrid-
ization chamber, and then washed in 0·03 SDS, 2XSSC,
1XSSC and 0·2 SSC solutions for 2 min. After washing, the
arrays were immediately scanned using a Genepix 4000 A
Scanner (Axon Instrument, Union City, CA). Images were
analyzed using Genepix Pro 3 software where spots with bad
quality were omitted. Data files generated by Genepix were
entered in Stanford microarray database. The spots with an
average intensity less than 2·5-fold above the background
were removed. A uniform scale factor was applied to all
measured intensities in order to normalize signal intensities
between Cy5 and Cy3. The data of 14 slides were normal-
ized in log-space using 
 
Lo
 
cally 
 
We
 
ighted Linear Regre
 
ss
 
ion
(Lowess) [22]. In order to identify the genes that were sig-
nificantly regulated by PEG-OB injection, we used the 
 
S
 
ig-
nificance 
 
A
 
nalysis 
 
M
 
icroarray (SAM) procedure, a validated
statistical technique for identifying differentially expressed
genes across high-density microarrays. SAM is a nonpara-
metric method by which a modified 
 
t
 
-statistic 
 
d
 
(
 
i
 
) = 
 
x
 
(
 
i
 
)/
[
 
s
 
(
 
i
 
) + 
 
s
 
0
 
] is calculated for the 
 
i
 
th
 
 gene, where 
 
x
 
(
 
i
 
) is the
mean of the log
 
2
 
 ratio data across all seven experiments and
 
s
 
(
 
i
 
) is the appropriately scaled standard deviation. The
quantity 
 
s
 
0
 
 is an adjustment factor derived from the data
which attempts to make 
 
d
 
(
 
i
 
) independent of 
 
s
 
(
 
i
 
). Because
the null hypothesis was that there was no treatment effect,
we tested whether the expected value of the log
 
2
 
 ratio is 0
in the statistic 
 
d
 
(
 
i
 
). The FDR (False Discovery Rate)
method controls the expected value of the number of false
positives to the total number of genes. For this experiment
the FDR was set at a value of 5%.
 
Quantification of mRNA levels by real-time PCR
 
Total RNA was extracted using Rneasy, as described earlier.
Reverse transcription was performed with 1 
 
µ
 
g total RNA
for each biopsy, and 10 ng cDNA was used as template for
RT-PCR as recommended by the manufacturer (Applied
Biosystems, Foster City, CA). We used 18S ribosomal RNA as
control to normalize gene expression (Applied Biosystems).
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The PCR was performed on the ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Minne-
apolis, MN) using the TaqMan Reverse Universal PCR
Master Mix and Assays-on-Demand Gene Expression
probes (Applied Biosystems) which contain a mixture of
forward and reverse oligonucleotide primers and a specific
TaqMan probe (Applied Biosystems).
The probe was labelled at the 5
 
′
 
 end with the reporter
dye, 6-carboxy-fluorescein (FAM) and at the 3
 
′
 
 end with
the quencher, 6-minor groove binder (MGB). The assay
identification number of the probes used are available on
the Applied Biosystem website.
Each reaction well contained cDNA, TaqMan PCR
Master Mix, 900 nmol L
 
−
 
1
 
 of each primer and 250 nmol L
 
−
 
1
 
of TaqMan probe. Cycling parameters were standardized
as 50 
 
°C for 2 min, 95 for 10 min, then 40 cycles of 95 °C
for 15 s and 60 °C for 1 min.
TaqMan reagent-based chemistry uses a fluogenic probe
to enable detection of a specific PCR product as it accu-
mulates during PCR cycles. When both quencher and
reporter are attached to the probe, reporter dye emission is
quenched. During each extension cycle at 60 °C, the
polymerase cleaves the reporter dye from the probe. After
being separated from the quencher, the reporter dye emits
its characteristic fluorescence.
A standard curve for each primer pair was obtained using
serial dilutions of WAT cDNA. A standard curve for serial
dilutions of 18S rRNA was similarly generated. The Ct rep-
resents the threshold cycle number at which the fluores-
cence signal is linearly increasing above background. The
Ct readings for unknown samples were used to calculate the
amount of each target gene relative to 18 S. The relative
standard curve method (Applied Biosystems) was used to
calculate the amplification difference between the before
and after PEG-OB treatment for each primer set.
Isolation of human white adipocytes and stroma 
vascular fraction
To determine whether differentially expressed genes were
mainly expressed in adipocytes, stroma vascular fraction
(SVF) or equally in adipocytes and SVF, we performed sets of
experiments aimed at isolating adipocytes from the stromal
cells, as described [20]. Briefly, stroma vascular fraction and
adipocytes were separated after adipose tissue digestion
and centrifugation. Total RNAs obtained from adipocytes
and SVF cells were extracted and a set of microarray experi-
ments were realized to distinguish genes expressed in adi-
pocyte from those expressed in SVF cells [20].
Capture of enriched functions after PEG-OB treatment
A functional profiling of PEG-OB regulated genes was real-
ized by using the Gene Ontology Consortium (GO, http://
www.geneontology.org/), which provides a controlled
vocabulary to describe gene and gene product attributes in
any organism [23]. We used GO through an ‘in-house’ auto-
mated annotation procedure (Henegar C, Bioinformatics in
revision). In order to assure a correct over-representation
analysis, LocusLink numbers were used as the standard
gene accession system (SGA), allowing us to map gene iden-
tifiers to GO functional annotations in an unequivocal way.
The GO hierarchical structure allows the characterization
of genes with a variable biological term precision (generic
terms and/or more specific terms based on the hierarchical
levels), and then the annotation procedure aimed to favour
the selection of the most specific GO categories against
more general ones. A gene-enrichment measure was
computed for each GO category by restricting annotation
inheritance only to the genes directly related to its direct
subsumes within the ontological hierarchy. The significance
of the gene enrichment for each GO category was assessed
by calculating a P-value. This P-value estimates the prob-
ability that the observed number of differentially regulated
genes (annotated by a specific GO category) could have
resulted from random distribution between the tested list
of differentially regulated genes in the experiment, for which
at least one GO annotation was identified, and a reference
list. The reference list included all the genes available on the
entire microarray, which were tested for differential regula-
tion during the experiment and which had at least one GO
annotation. As many of the identified GO categories had less
than five annotations, a unilateral Fisher exact test was used
for P-value calculations. Only GO categories showing signifi-
cant gene enrichment (after P-value correction for a 5% false
discovery rate) were selected and used for further process-
ing. In order to facilitate the analysis of functional profiles,
we clustered together all related GO categories, based on the
sharing of a significant number of annotated genes (Henegar
C, Bioinformatics in revision). As for the individual GO cat-
egories, a P-value of gene enrichment significance was cal-
culated for each of the identified clusters, by using a unilateral
Fisher exact test, and then the clusters were ranked based
on the statistical significance of the gene space coverage.
Gene annotation procedure was realized separately for each
of the three available ontologies: molecular function, bio-
logical process and cellular component. As ‘biological pro-
cess’ annotations were the more exhaustive and immediately
comprehensive, they are presented in this study.
The second method used is the visualization tool Gen-
MAPP (Gene Map Annotator Pathway Profiler) version 2·0
(http://www.genmapp.org). This is a program for viewing
and analyzing microarray data on microarray pathway pro-
files (MAPPs) representing biological pathways or any other
functional grouping of genes [24]. Microarray pathway pro-
files are generated from several public and commercial path-
way resources currently in existence, including:
• GO database and G-protein Coupled Receptor Database
(http://www.gpcr.org, database on G-protein and their
interactions with their receptors) [25];
• a small number of MAPPs based on the KEGG database
(http://www.genome.ad.jp/kegg, database integrating knowledge
on molecular interaction networks in biological processes,
the information about the universe of genes and proteins,
and the information about the universe of chemical
compounds and reactions) [26];
• MAPPS specifically designed for GenMAPP.
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The MAPPS from the G-protein Coupled Receptor
Database, KEGG database and the specifically designed
MAPPS are called the local MAPPS. We imported the
median gene expression data of the significant gene group,
sorted by SAM, into the program and used GenMAPP to
illustrate pathways containing differentially expressed
genes. The obtained illustrations show presence and expres-
sion changes for the genes presented on the microarray
based on the analysis of PEG-OB treatment versus control.
All the gene expression data are dynamically linked to the
MAPPs with a tool called MAPPFinder [27]. For all the
imported genes MAPPFinder calculates the percentage of
genes measured that meet a user-defined criterion (fold
change > 1·4 or < −1·4) and a z-score. The z-score is a stand-
ardized difference-score using the expected value and stand-
ard deviation of the number of genes meeting the criterion
on a MAPP. The z-score attempts to take into account that
a larger fraction of changed genes is less likely to occur in
a large MAPP than is a small one.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was
performed with JMP statistic software (SAS Institute Inc.,
Cary, NC). Differences in means of clinical and biochemical
parameters of subjects before and after PEG-OB treatment
were determined using the Wilcoxon nonparametric paired
test. Significance of correlation between circulating levels of
CRP and SAA was examined using the nonparametric
Spearman’s rank.
Results
Effect of PEG-OB injection on clinical and 
biochemical parameters
The baseline characteristics of the subjects and changes
after 72 h of PEG-OB injection are shown in Table 1. While
the circulating leptin increased approximately 809-fold,
the weight of the subjects, insulin as well as the adipokine
adiponectin did not change after the PEG-OB injection
(Table 1). The inflammatory factors CRP and SAA tended
to increase after the PEG-OB injection. However, these
increases were not significant (CRP fold increase = 2·18,
P = 0·27; SAA fold increase = 3·35, P = 0·055). There was
a strong positive correlation between variations of circulat-
ing CRP and SAA levels under the PEG-OB injection
(r = 0·93, P < 0·0001).
PEG-OB treatment mobilized genes in human WAT
Our gene profiling experiment was performed with total
RNA preparation from WAT of seven healthy men before
and after 72 h of PEG-OB treatment, leading to a 809-fold
increase in circulating serum leptin. We started to analyze
the expression of 40 844 cDNAs printed on a glass slide.
After normalization, filtering procedures and use of the SAM
program, we found 1922 cDNAs with significant changes
using an estimated FDR of 5%. These cDNAs included
1822 downly expressed and 100 overexpressed genes.
Using RT-PCR, we confirmed the changes in expression
of nine genes, including chemokines (CCL5, CCL4,
XCL1), TNF superfamily factor 3 and other inflammatory-
related factors like cathepsin S, selectin L and neutrophile
cytosolic factor 4 (Table 2). In agreement with microarray
findings, MGST1 gene expression was not changed in RT-
PCR experiments.
Enriched functions of PEG-OB mobilized genes in 
WAT
We further searched for the functional classes that were
significantly captured by the PEG-OB injection in WAT.
Although no significant cluster of enriched functions was
identified in the group of overexpressed genes (data not
Table 2 Validation of microarray results using quantitative real-time quantitative PCR
 
 
Response to leptin UG cluster Name Ratio array Ratio RT-PCR P-value
Down Hs 234734 Lysozyme −2·39 −2·22 0·01
Hs 82848 Selectin L −2·13 −1·88 0·1
Hs 181301 Cathepsin S −1·91 −2·00 0·04
Hs 196352 Neutrophile cytosolic factor 4 −1·64 −1·56 0·07
Hs 76930 Synuclein alpha −2·07 −1·85 0·01
Hs 241392 Chemokines CCL5 −1·45 −1·63 0·1
Hs 75703 Chemokines CCL4 −1·45 −2·85 0·03
Hs 174228 Chemokine XCL1 −1·87 −2·63 0·03
Hs 371856 TNF superfamily 3 ligand −1·86 −2·27 0·09
Nonsignificant Hs 389700 Microsomal glutathion s transferase   1·16 −1·3 0·5
Fold changes in mRNA levels of 10 randomly chosen genes were determined by real-time PCR (RT-PCR) on total RNA from the 
seven subjects.
P-values were calculated using the nonparametric Wilcoxon test.
Microarray experiments were performed on amplified RNA from seven subjects. Microsomal glutathione S-transferase (MGST1) is a 
control gene of which the fold change did not significantly change in real-time PCR and microarray experiments.
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shown), the GO biological process based on automatic
annotation revealed different sets of enriched functions in
the group of down-regulated genes. Three significant func-
tional clusters were enlightened as illustrated in Fig. 1. The
first two significant clusters included genes related to immu-
nity and inflammatory functions (Fig. 1). The third cluster
was related to embryonic development functions.
For examination of more specific changes after the PEG-
OB injection, the functional grouping of genes modified by
the PEG-OB injection was systematically evaluated for dif-
ferential regulation using the visualization tool GenMAPP.
We found genes significantly modified by the PEG-OB
injection in eight local MAPPS (Table 3). In agreement with
our first functional analysis, the inflammatory response
pathway was among the local pathways most down-regulated
after the PEG-OB injection (Table 3).
Other local MAPPs identified were nucleotide metabo-
lism, peptide GPCRs, apoptosis, TGF beta signalling, syn-
thesis and degradation of ketone bodies, pentose phosphate
pathway and proteasome degradation (Table 3). The
MAPPs were ranked with a decreasing z-score. More
positive z-scores suggest with more confidence that the
correlation between the expression changes of the genes in
this MAPP are not occurring by chance alone. Taken
together, these results indicate that adipose tissue genes
related to inflammation and immunity were significantly
down-regulated by the supraphysiological dose of the
PEG-OB injection.
Figure 1 Schematic representation of enriched functions in the group of polyethylene glycol-leptin down-regulated genes. The clusters 
of enriched functions are listed by P-value score (after adjustment with the Benjamini & Hochberg FDR method) and the figure shows 
the three significant clusters of genes. The number of genes annotated by a given gene ontology function (biological process) is indicated 
in the parenthesis.
Table 3 GenMAPP pathways affected by leptin treatment
 
Pathway MAPP name z-score
Genes 
changed
Reporters 
present
Genes on
MAPP
Hs_inflammatory response pathway 1·588 3 5 31
Hs_nucleotide metabolism 1·588 3 5 16
Hs_peptide GPCRs 1·377 4 8 69
Hs_apoptosis 0·977 2 4 43
Hs_TGF beta signalling pathway 0·831 5 13 51
Hs_synthesis and degradation of ketone bodies 0·692 1 2 5
Hs_pentose phosphate pathway 0·692 1 2 7
Hs_proteasome degradation 0·285 5 16 42
The table shows a ranked list of processes with a relatively high number of gene expression values found to be changed. The z-score is 
calculated as the number of genes changed (fold change > 1·4) in a pathway minus the number of expected changes based on the number 
of genes present in the pathway MAPP and the total fraction of genes changed for all MAPPs, divided by the standard deviation of the 
observed number of changes in all MAPPs. High z-scores indicate pathways where relatively many changes occurred. Note that the 
z-score also depends on the coverage of the pathway genes by the successfully annotated microarray reporter content. Next to the number 
of changed genes, the number of reporters for that pathway on the array and the total number of genes in the pathway MAPP are also 
given (cf. Methods).
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Table 4 Transcriptional effects of leptin on inflammatory related genes
 
G cluster Gene name Fold change
Chemokines
Hs.81564 platelet factor 4 (chemokine (C-X-C motif ) ligand 4) −1·32
Hs.82407 chemokine (C-X-C motif ) ligand 16 −1·33
Hs.80420 chemokine (C-X3-C motif ) ligand 1 −1·41
Hs.50002 chemokine (C-C motif ) ligand 19 −1·43
Hs.75703 chemokine (C-C motif ) ligand 4 −1·45
Hs.131342 chemokine (C-C motif ) ligand 26 −1·46
Hs.241392 chemokine (C-C motif ) ligand 5 −1·46
Hs.2164 pro-platelet basic protein (chemokine (C-X-C motif ) ligand 7) −1·49
Hs.16530 chemokine (C-C motif ) ligand 18 (pulmonary and activation-regulated) −1·76
Hs.174228 chemokine (C motif ) ligand 1 −1·88
Chemokine receptors
Hs.421986 chemokine (C-X-C motif ) receptor 4 −1·42
Hs.458436 chemokine (C-C motif ) receptor-like 2 −1·47
Hs.301921 chemokine (C-C motif ) receptor 1 −1·51
Hs.395 chemokine (C-C motif ) receptor 2 −1·57
Hs.78913 chemokine (C-X3-C motif ) receptor 1 −1·80
Cytokines, TNF superfamily and interferons
Hs.105656 small inducible cytokine subfamily E, member 1 (endothelial monocyte-activating) −1·31
Hs.130210 interleukin 6 (interferon, beta 2) −1·34
Hs.168132 interleukin 15 −1·36
Hs.58831 regulator of Fas-induced apoptosis −1·37
Hs.856 interferon, gamma −1·38
Hs.170359 interleukin 16 (lymphocyte chemoattractant factor) −1·38
Hs.415839 tumour necrosis factor (ligand) superfamily, member 12 −1·44
Hs.83795 interferon regulatory factor 2 −1·49
Hs.387871 tumour necrosis factor (ligand) superfamily, member 10 −1·56
Hs.845 interleukin 13 −1·58
Hs.169274 interferon-induced protein with tetratricopeptide repeats 2 −1·60
Hs.376208 lymphotoxin beta (TNF superfamily, member 3) −1·87
Cytokines and TNF superfamily receptors
Hs.143527 interleukin 1 receptor accessory protein −1·35
Hs.272410 toll-like receptor 8 −1·42
Hs.362807 interleukin 7 receptor −1·43
Hs.144748 interferon (alpha, beta and omega) receptor 1 −1·44
Hs.1314 tumour necrosis factor receptor superfamily, member 8 −1·47
Hs.74647 T-cell receptor alpha locus −1·80
Adhesion
Hs.13572 calcium modulating ligand   1·56
Hs.10247 activated leucocyte cell adhesion molecule −1·35
Hs.2257 vitronectin (serum spreading factor, somatomedin B, complement S-protein) −1·36
Hs.17483 CD4 antigen (p55) −1·47
Hs.3003 CD3E antigen, epsilon polypeptide (TiT3 complex) −1·48
Hs.54517 ficolin (collagen/fibrinogen domain containing lectin) 2 (hucolin) −1·48
Hs.381568 immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides −1·49
In our study in healthy nonobese males, we observed a
decreased expression of factors bearing proinflammatory
properties in human adipose tissue under PEG-OB treat-
ment. Several of these genes encoded for inflammatory
factors are potentially secreted, such as chemokines with
Cys (XCL1), Cys-Cys (CCL 2, 4, 5, 18, 19, 26) Cys-x-Cys
(CXCL 7, 4, 16) and Cys-x3-Cys (CX3CL1) motifs. These
molecules have well-known chemotactic properties and
proinflammatory effects. Other secreted factors are cytokines
or related factors such as several members of the tumour
necrosis factor superfamily ligand, interleukins (IL6, IL15,
IL16, IL13), interferon gamma (INFγ) and interferon
inducible protein. These changes are associated with a
decreased expression of many chemokines and interleukin
receptors. Other genes encoded proteins with protease
(cathepsin S, lysozyme) activities that have the ability to
degrade antigens presented to immune cells. Genes encod-
ing proteins that enable adhesion of immune cells, such as
integrin alpha X, selectin L, selectin P ligand, carcino-
embryonic antigen-related cell adhesion, CD4 and CD3
antigens, were also mobilized (Table 4).
To determine whether the major down-regulated PEG-OB
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Hs.89575 CD79B antigen (immunoglobulin-associated beta) −1·56
Hs.95327 CD3D antigen, delta polypeptide (TiT3 complex) −1·58
Hs.407861 alpha-2-glycoprotein 1, zinc −1·60
Hs.79630 CD79A antigen (immunoglobulin-associated alpha) −1·63
Hs.838 CD80 antigen (CD28 antigen ligand 1, B7-1 antigen) −1·99
Hs.434918 carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) −2·00
Hs.82848 selectin L (lymphocyte adhesion molecule 1) −2·13
Hs.385521 integrin, alpha X (antigen CD11C (p150), alpha polypeptide) −2·31
Hs.423077 selectin P ligand −2·99
Signal transduction
Hs.753 formyl peptide receptor 1 −1·42
Hs.433300 Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide −1·46
Hs.46 platelet-activating factor receptor −1·51
Hs.126384 Fc fragment of IgG, low affinity IIb, receptor for (CD32) −1·53
Hs.44439 suppressor of cytokine signalling 4 −1·58
Hs.381027 colony stimulating factor 3 receptor (granulocyte) −1·65
Hs.46348 bradykinin receptor B1 −1·84
Transcriptional factors
Hs.14453 interferon consensus sequence binding protein 1   1·83
Hs.374357 nuclear factor related to kappa B binding protein −1·31
Hs.433759 barrier to autointegration factor 1 −1·41
Hs.83795 interferon regulatory factor 2 −1·49
Hs.25647 v-fos FBJ murine osteosarcoma viral oncogene homolog −1·50
Hs.105434 interferon stimulated gene 20 kDa −1·62
Hs.41691 basic leucine zipper transcription factor, ATF-like −1·94
Hs.153837 myeloid cell nuclear differentiation antigen −1·96
Other related inflammatory genes
Hs.79241 B-cell CLL/lymphoma 2   1·64
Hs.407442 Homo sapiens TCRgamma alternate reading frame protein (TCRg) mRNA, complete cds −1·33
Hs.169998 bone marrow stromal cell antigen 1 −1·38
Hs.2253 complement component 2 −1·38
Hs.146559 angiopoietin-like factor −1·39
Hs.381568 immunoglobulin J polypeptide, linker protein for immunoglobulin alpha and mu polypeptides −1·49
Hs.406238 aldehyde oxidase 1 −1·50
Hs.2563 tachykinin, precursor 1 (substance K, substance P, neurokinin 1, neurokinin 2, neuromedin L, −1·55
neurokinin alpha, neuropeptide K, neuropeptide gamma)
Hs.100194 arachidonate 5-lipoxygenase-activating protein −1·57
Hs.407861 alpha-2-glycoprotein 1, zinc −1·60
Hs.46465 T cell, immune regulator 1, ATPase, H + transporting, lysosomal V0 protein a isoform 3 −1·62
Hs.196352 neutrophil cytosolic factor 4, 40 kDa −1·64
Hs.414332 2′-5′-oligoadenylate synthetase 2, 69/71 kDa −1·81
Hs.105407 ectodermal dysplasia 1, anhidrotic −1·85
Hs.181301 cathepsin S −1·91
Hs.449439 Homo sapiens TCR BV3 mRNA for T cell receptor beta chain (CDR3 region), partial cds, 
isolate:HTLV-1 myopathy case 3, clone:Tax tetramer-5.
−1·95
Hs.949 neutrophil cytosolic factor 2 (65 kDa, chronic granulomatous disease, autosomal 2) −1·99
Hs.2200 perforin 1 (pore forming protein) −2·30
Hs.234734 lysozyme (renal amyloidosis) −2·39
G cluster Gene name Fold change
Table 4  (cont’d)
effect in WAT was related to the decrease of PEG-OB recep-
tor (Ob-Rb) expression under PEG-OB treatment we ana-
lyzed the individual variation in expression of Ob-Rb by RT-
PCR in seven subjects. The microarray experiments did not
reveal a significant change. The results obtained showed that
the PEG-OB injection did not significantly change the Ob-
Rb expression (fold change = 0·95, P-value > 0·05; data not
shown).
Cellular origin of inflammatory mobilized genes in 
WAT
As adipose tissue contains not only adipocytes but also
stromal-vascular cells, including fibroblastic connective
tissue cells, preadipocytes (not yet filled with lipids) as well
as leucocytes and macrophages [28], we further examined
whether the inflammatory-related genes regulated by the
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PEG-OB injection in humans were expressed mostly in
adipocytes or in the stroma vascular fraction. Mature adi-
pocytes were separated from the SVF as described in the
Materials and Methods section. Among the clusters (cluster
1 and 2, Fig. 1) related to immunity and inflammation path-
ways, we sorted either genes typical of adipocytes or genes
mostly expressed in SVF or in both fractions. As shown in
Fig. 2, most of the inflammatory related genes were mainly
expressed in the SVF or equally expressed in adipocyte and
SVF. The fraction of genes mainly expressed in adipose cells
was faint.
Discussion
The existence of the leptin effect on WAT or isolated adi-
pocytes is a matter of controversy. The leptin target genes
in human WAT are unknown. Although both mRNA and
protein of the leptin receptor (Ob-Rb) were detected on
human adipocytes [29], leptin treatment in different sys-
tems led to divergent results. Several studies provide some
evidences of an effect of leptin both in vitro on isolated
murine adipocytes [30] and in vivo in WAT from rodents
[31,32]. In contrast, in other studies no effect of leptin on
WAT gene expression was found [33,34]. Our experiment
showed that the supraphysiological PEG-OB injection in
healthy individuals induced transcriptional changes in WAT
and most of these genes were downly expressed. We also
found that most of these genes belong to the inflammatory
and immune functional class.
In vitro and in vivo studies have suggested a potential role
for leptin in modulating the immune response [8]. The
leptin receptor is structurally related to the class 1 cytokine
receptor family and has been shown to have signalling cap-
abilities of interleukin-6-type cytokine receptors [35]. The
first observations were carried out on rodents with genetic
leptin (ob/ob) or leptin receptor (db/db) deficiency. These
mice elicit macrophage phagocytosis and the overexpression
of proinflammatory cytokines [36]. Administration of exo-
genous leptin to ob/ob mice reversed the inflammation asso-
ciated phenotype [36]. In most of the available publications,
a proinflammatory function of leptin on immune cells
(lympocytes, monocytes) was described [37,38]. No study
has demonstrated such effects in human adipose tissue or
adipocytes. In addition, in human monocytes, leptin was
shown to induce the expression and the secretion of IL-1Ra,
an interleukin widely recognized as an anti-inflammatory
factor in vitro [39]. Another study showed that an increase
in circulating leptin in monkey blunts the cytokine response
to an inflammatory challenge [40].
One explanation of the down-regulated effect of PEG-OB
in WAT might be associated with the supraphysiological
dose of PEG-OB used in these healthy subjects. As
expected, the PEG-OB injection induced very high plasma
leptin levels in all the subjects. At this dose, many physio-
logical pathways could be down-regulated. In this regard,
we observed that most of the genes were down-regulated in
our experience, including factors involved in metabolism,
signal transduction, extracellular matrix and cytoskeleton.
To date, all human PEG-OB injection trials have not
shown large effects. In the present study no other major
physiological change on energy metabolism or hormonal
status was observed. However, analyzing the pro-inflammatory
status in one of our weight reduction studies using the PEG-
OB injection, we found an additional significant decrease
of inflammatory markers as a whole [41]. It was concluded
that the apparently higher decline in inflammatory para-
meters in the PEG-OB treated group may be related to the
higher weight loss in this group. The present study provides
additional information regarding the anti-inflammatory
effect of PEG-OB especially in WAT.
In our study, we observed a trend toward an increase of
circulating levels of the pro-inflammatory factors (CRP and
SAA) after the PEG-OB injection. The mechanism by
which leptin increased CRP and SAA in this study is not
known but could relate to an acute-phase response. There
is no confirmation that CRP and SAA could be produced
by the WAT in this context. Indeed, in nonobese subjects
CRP and SAA are mainly produced by the liver [42]. The
CRP and SAA are classical and highly sensitive acute-phase
proteins; plasma levels that typically increase by 100-fold
or more during inflammation. The twofold increase in CRP
levels and threefold increase of SAA upon the PEG-OB
injection are indicative of only a weak inflammatory
response and may result from the direct interaction of leptin
on hepatocytes via its receptor. This kind of interaction has
been reported to induce IL-6-type responses [43,44]. These
observations are in line with the strong correlation found
between CRP and SAA changes upon a PEG-OB injection.
Figure 2 Cellular origin of inflammatory related genes in white adipose tissue. The two clusters represent the enriched functions isolated 
with the gene ontology annotation system. The yellow, red and orange boxes represent the number of genes overexpressed in the adipocytes, 
stroma vascular fraction (SVF) fraction and equally in both the adipocytes and SVF fraction, respectively.
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In our study, we showed a decreased gene expression 3 days
after PEG-OB administration in WAT, but we cannot exclude
that in the first few days the inflammatory gene expression
responded differently to PEG-OB administration. To inves-
tigate this possibility, future kinetic studies might be of interest.
Conclusions
In this study, we have characterized the WAT gene expres-
sion profile after 3 days in response to the administration
of PEG-OB in a single supraphysiological dose. Most of
these genes showed a decreased expression after the PEG-
OB injection. Sorting the PEG-OB regulated genes into
functional classes, we observed that genes related to the
inflammation and immunity classes were significantly affected
by PEG-OB.
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